Evidence map›Paper›PMID 42159078›Full record

ArticleThe Cochrane database of systematic reviews2026

Dose reduction and discontinuation of non-tumor necrosis factor (TNF) biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for people with rheumatoid arthritis in remission or low disease activity.

Yuanteng J Li, Maria Angeles Lopez-Olivo, Yimin Geng, Jean H Tayar, Maria E Suarez-Almazor

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Cochrane database of systematic reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuanteng J LiGeneral Internal Medicine - Rheumatology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0009-0002-2611-5562
Maria Angeles Lopez-OlivoDepartment of Health Services Research, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-5165-8393
Yimin GengResearch Medical Library, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-8491-3151
Jean H TayarGeneral Internal Medicine - Rheumatology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-9018-3802
Maria E Suarez-AlmazorGeneral Internal Medicine - Rheumatology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-5381-5797

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis is a protocol for a Cochrane Review (intervention). The objectives are as follows: To determine the benefits and harms of dose reduction or discontinuation of non-TNF biologic or targeted synthetic DMARDs in people with rheumatoid arthritis who are in remission or have low disease activity.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidHumansMethotrexateRandomized Controlled Trials as TopicRemission InductionSystematic Reviews as TopicTreatment InterruptionTumor Necrosis Factor-alphaAntirheumatic AgentsMethotrexateTumor Necrosis Factor-alpha

Identifiers

PMID42159078
PMCPMC13188191

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.